Clinical Trials | March 23, 2023
Osteoarthritis candidate MM-II showed durable pain relief in Global Phase 2b study
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
The audit is a pre-approval inspection for three products filed from the facility
MoES have identified a potent Anti-cancer molecule named GS/IICT5/6
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Proposed combination enhances Pfizer’s position as a leading company in oncology
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
Subscribe To Our Newsletter & Stay Updated
